On page 900, the first Key Point, which reads “There was no evidence of fibrinolytic activation in patients with hypoproliferative anemia” should read “No evidence of fibrinolytic activation was observed in patients with hypoproliferative thrombocytopenia.”
. 2023 Jul 3;7(13):3022. doi: 10.1182/bloodadvances.2023010270
Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
Collection date 2023 Jul 11.
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PMCID: PMC10362531 PMID: 37390313
This corrects the article "Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia" on page 900.